AltruBio
Phase 2Phase II Potency improved version of ALTB-168, Phase 1 trial in healthy volunteers completed. Ph2a trial in UC patients initiated in late 2023.
Founded
2018
Focus
AntibodiesBiologics
About
Phase II Potency improved version of ALTB-168, Phase 1 trial in healthy volunteers completed. Ph2a trial in UC patients initiated in late 2023.
Funding History
5Total raised: $801M
Series B$225MUndisclosedMay 21, 2024
Series B$225MBVF PartnersDec 15, 2023
Series B$225MBVF PartnersOct 15, 2023
Series A$63MBVF PartnersJun 15, 2021
Company Info
TypePrivate
Founded2018
LocationSan Francisco, United States
StagePhase 2
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile